Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 15/20 | 1.00 |
| ▸ | FNTB | P49356 | 15/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2722114 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL8492288 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL17534949 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL16111993 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| Trifluoroacetic Acid SCHEMBL5084899 | 0.95 | FNTA (0.90) | FNTAFNTBPGGT1BTDP1 | |
| Trifluoroacetic Acid SCHEMBL29394662 | 0.95 | FNTA (0.90) | FNTAFNTBPGGT1BTDP1 | |
| Trifluoroacetic Acid SCHEMBL5084894 | 0.95 | FNTA (0.90) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL14169168 | 0.94 | FNTA (0.88) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL8365606 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL8586036 | 0.92 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | claimed |
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | disclosed |
| US-20240139315-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-05-02 | — | — | US | disclosed |
| CN-111655228-B | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11883491-B2 | Compositions and methods for prevention and treatment of hearing loss | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-114981298-A | Compositions and methods for preventing and treating hearing loss | 听治疗有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220133730-A1 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | TING THERAPEUTICS LLC (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114364267-A | Novel flavor composition, preparation method and application thereof | 国际香料和香精公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021118924-A2 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS | TING THERAPEUTICS LLC (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021081110-A2 | PEPTIDES AND USE THEREOF | ANEXIGEN, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| CN-111655228-A | Compositions and methods for preventing and treating hearing loss | J·左 | 2020-09-11 | — | — | CN | disclosed |
| US-20200093923-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVEN (US) | 2020-03-26 | — | — | US | disclosed |
| EP-3618807-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | Zuo, Jian (US) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018204226-A1 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS GROUP, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| US-20090239936-A1 | Prophylactic and Therapeutic Agent for Cancer | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-2025347-A1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058751-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | KRAS, NRAS, TP53 | FNTA 1114/4885FNTB 1259/4885PGGT1B 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.